




FIG. 1

	SCR ^a	Randomized Treatment Period																																			Post Treatment Period ^d
		RND ^b																																			
		EOT ^c																																			
Week	-4(±1)	0	2	4	6	8	10	12	14	16	18	20	22	24	26	28	30	32	34	36	38	40	42	44	46	48	50	52	56	60	64						
Visit	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26	27	28	29	30	31						
Informed Consent/ Assent ^f	X																																				
Inclusion/Exclusion Criteria	X	X																																			
Patient Demography	X																																				
Medical/Surgical History ^g , and Reversibility ^h	X																																				
Physical Examination	X													X															X			X					
Menstruation Status ⁱ	X	X	X	X	X	X	X	X		X	X		X	X	X	X		X		X		X	X	X	X		X		X			X					
Vital Signs ^j (Including Height and Weight)	X	X	X	X	X	X	X	X		X			X	X	X	X		X		X		X	X	X	X		X		X	X	X	X					
Dispense or Download Electronic Diary/PEF Meter ^k	X	X	X	X	X	X	X	X		X			X	X	X	X		X		X		X	X	X	X		X		X	X	X	X					
Health Care Resource Utilization (HCRU)		X					X						X							X					X							X					
Randomization ^b		X																																			
Call IVRS/IWRS	X	X	X	X	X	X	X	X		X	X		X	X	X	X		X		X		X	X	X	X		X		X			X					
Treatment																																					

FIG. 2

	SCR ^a	Randomized Treatment Period																																Post Treatment Period ^d
		RND ^b																EOT ^c																
Week	-4(+1)	0	2	4	6	8	10	12	14	16	18	20	22	24	26	28	30	32	34	36	38	40	42	44	46	48	50	52	56	60	64	EOS		
Visit	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26	27	28	29	30	31			
Investigational Product Administration ^f	X	X	X	X	X	X	X	X	X ^m	X	X ^m	X	X ^m	X	X ^m	X	X ^m	X	X ^m	X	X ^m	X	X ^m	X	X ^m	X	X ^m	X	X ^m					
Dispense/Review of Diary for Home Dosing ^m (Optional) by Parent/Caregiver							X			X			X			X		X			X			X						X				
Efficacy Assessments																																		
Spirometry ⁿ	X	X ^o	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X		
Post-Bronchodilator FEV1 ⁿ		X	X	X	X	X	X	X	X				X							X														
Patient Reported Outcomes / HRQoL																																		
ACQ-IA ^p	X	X ^o	X	X	X	X	X	X	X	X				X			X		X		X		X		X		X					X		
PAQLQ (S)-IA (for Patients >7 Years Old at Randomization V2) ^p		X						X						X					X										X				X	
PRQL-IA ^q		X						X						X															X				X	
EQ-5D-Y for Children		X												X															X				X	
Patient Reported Outcomes (Caregiver)																																		

FIG. 2
(Continued)

	SCR ^a	Randomized Treatment Period																															Post Treatment Period ^d
		RND ^b	EOT ^c																														
			Week Visit	0	2	4	6	8	10	12	14	16	18	20	22	24	26	28	30	32	34	36	38	40	42	44	46	48	50	52	56	60	
		1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26	27	28	29	30	31	
PACQLQ (for Caregivers of Patients > 7 Years Old at Randomization v2)			X											X							X									X		X	
PK, PD, Pharmacogenetics																																	
Blood Biomarkers ^f			X											X																X			
Total IgE, and Antigen-Specific IgEs			X											X																X			
Antigen-Specific IgG4 Panel ^g			X												X															X			
Systemic Drug Concentration ^h			X			X								X																X			X
Exhaled NO ^u	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X
Blood for DNA Extraction (Optional) ^v																																	
← X →																																	
Safety Assessments																																	
Total IgG, IgG Subclasses, IgM, IgA		X												X																X			X
Anti-Drug Antibodies ^w		X							X					X																X			X

FIG. 2
(Continued)

[illegible]

FIG. 2
(Continued)

	SCR ^a	Randomized Treatment Period																														Post Treatment Period ^d	
		RND ^b																														EOT ^c	EOS
Week	-4(±1)	0	2	4	6	8	10	12	14	16	18	20	22	24	26	28	30	32	34	36	38	40	42	44	46	48	50	52	56	60	64		
Visite	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26	27	28	29	30	31		
Blood Sample Collection ^{aa} for Assessment of IgG Response to Vaccination					X ^{aa}			X ^{aa}					X ^{aa}							X ^{aa}							X ^{aa}						

FIG. 2
(Continued)

Endpoint	Population	Placebo	Dupilumab	Treatment Effect Dupi vs. Pbo (p-value)	EU Hierarchy	US Hierarchy
Exacerbation	Type 2	0.748 (114)	0.305 (236)	0.407 (<.0001)	1	3
	EOS $\geq$ 0.15	0.816 (108)	0.318 (223)	0.390 (<.0001)	2	2
	EOS $\geq$ 0.3	0.665 (84)	0.235 (175)	0.353 (<.0001)	3	1
FEV1pp, Δ from BL @wk12	Type 2	5.32 (110)	10.53 (229)	5.21 (0.0009)	4	6
	EOS $\geq$ 0.15	5.65 (104)	10.63 (216)	4.98 (0.0020)	5	5
	EOS $\geq$ 0.3	4.83 (80)	10.15 (168)	5.32 (0.0036)	6	4
ACQ7-1A, Δ from BL@wk24 [Range 0-6, MCID 0.5]	Type 2	-1.00 (110)	-1.33 (227)	-0.33 (0.0001)	7	9
	EOS $\geq$ 0.15	-0.98 (104)	-1.33 (214)	-0.36 (<.0001)	8	8
	EOS $\geq$ 0.3	-0.88 (80)	-1.34 (166)	-0.46 (<.0001)	9	7
Exacerbation		0.705 (62)	0.271 (141)	0.384 (0.0004)	10	10
FEV1 pp, Δ from BL	FeNO $\geq$ 20	4.62 (62)	11.36 (141)	6.74 (0.0018)	11	11
ACQ7-1A, Δ from BL		-0.96 (62)	-1.37 (141)	-0.41 (0.0006)	12	12
Exacerbation	ITT	0.608 (135)	0.278 (273)	0.458 (<.0001)	13	13
FEV1 pp, Δ from BL		5.17 (131)	9.85 (264)	4.68 (0.0012)	14	14

FIG. 3

Endpoint	Population	Placebo	Dupilumab	Treatment Effect Dupi vs. Pbo (p-value)	EU Hierarchy	US Hierarchy
Exacerbation High ICS Subgroup	Type 2 + H-ICS	1.145 (50)	0.420 (102)	0.367 (0.0004)	15	17
	Eos ≥ 0.15 + H-ICS	1.393 (47)	0.449 (94)	0.322 (0.0001)	16	16
	Eos ≥ 0.3 + H-ICS	0.697 (41)	0.251 (74)	0.360 (0.0019)	17	15
	FeNO >20 + H-ICS	1.045 (28)	0.374 (64)	0.358 (0.0060)	18	18
	ITT + H-ICS	0.844 (60)	0.362 (120)	0.429 (0.0021)	19	19
Feno Δ from BL@wk12	Type 2	-1.13 (110)	-18.97 (226)	-17.84 ($<.0001$)	20	22
	EOS ≥ 0.15	-0.88 (104)	-18.76 (213)	-17.88 ($<.0001$)	21	21
	EOS ≥ 0.3	-0.81 (80)	-21.40 (165)	-20.59 ($<.0001$)	22	20
	FeNO ≥ 20	-2.49 (62)	-30.50 (140)	-28.00 ($<.0001$)	23	23
	ITT	-1.33 (130)	-16.09 (261)	-14.76 (0.0004)	24	24

FIG. 3
(Continued)




FIG. 4




FIG. 5

11/81





FIG. 6

12/81



Endpoints*	Populations Identified by Markers of Type 2 Inflammation								ITT	
	Type2		EOS ≥ 0.3		EOS ≥ 0.15		FeNO ≥ 20*			
	VOYAGE	QUEST	VOYAGE	QUEST	VOYAGE	QUEST	VOYAGE	QUEST	VOYAGE	QUEST
	VOYAGE	QUEST	VOYAGE	QUEST	VOYAGE	QUEST	VOYAGE	QUEST	VOYAGE	QUEST
Exacerbation Reduction	59.3%	54/58%	64.7%	66/67%	61%	56/60%	61.6%	65/61%	54.2%	48/46%
FEV pp Δ from BL @wk 12	5.21	5.35/4.9	5.32	6.71/8.57	4.98	5.7/5.04	6.74	7.24/7.78	4.68	4.45/4.36
ACQ-7-IA Δ from BL @wk 24	-0.33	-0.39/-0.27	-0.46	-0.58/-0.44	-0.36	-0.42/-0.28	-0.41	-0.53/-0.32	-0.28	-0.35/-0.20

FIG. 7

	Type 2 Population			Eos $\geq$ 0.3 Giga/L Population			Quest
	PBO (N=114)	Dupi (N=236)	All (N=350)	PBO (N=84)	Dupi (N=175)	All (N=259)	T2 (1519)
Age (Year), Mean (SD)	9.0 (1.6)	8.9 (1.6)	8.9 (1.6)	9.0 (1.5)	8.9 (1.6)	9.0 (1.6)	47.6 (15.3)
Female, n (%)	36 (31.6%)	84 (35.6%)	120 (34.3%)	26 (31.0%)	59 (33.7%)	85 (32.8%)	928 (61.1)
Weight (kg), Mean (SD)	37.08 (11.61)	35.60 (10.00)	36.09 (10.56)	36.97 (11.70)	35.45 (9.98)	36.94 (10.57)	79.56 (19.95)
<= 30kg	36 (31.6%)	76 (32.2%)	112 (32.0%)	28 (33.3%)	56 (32.0%)	84 (32.4%)	NA
> 30kg	78 (68.4%)	160 (67.8%)	238 (68.0%)	56 (66.7%)	119 (68.0%)	175 (67.6%)	NA
Medium ICS, n (%)	64 (56.1%)	131 (55.5%)	195 (55.7%)	43 (51.2%)	98 (56.0%)	141 (54.4%)	720 (47.4)
High ICS, n (%)	50 (43.9%)	102 (43.2%)	152 (43.4%)	41 (48.8%)	74 (42.3%)	115 (44.4%)	785 (51.7)
Severe Exacerbations/year, Mean (SD)	2.18 (1.55)	2.61 (2.58)	2.47 (2.30)	2.37 (1.71)	2.78 (2.90)	2.64 (2.58)	2.12 (2.22)
Pre-BD FEV1 pp, Mean (SD)	78.36 (14.51)	77.66 (14.38)	77.89 (14.40)	77.87 (15.19)	76.37 (14.60)	76.85 (14.78)	58.31 (13.48)
Pre-BD FEV1 pp <80%, n (%)	59 (51.8%)	116 (49.2%)	175 (50.0%)	45 (53.6%)	93 (53.1%)	138 (53.3%)	NA
Pre-BD FEV1 pp $\geq$ 80%, n (%)	55 (48.2%)	120 (50.8%)	175 (50.0%)	39 (46.4%)	82 (46.9%)	121 (46.7%)	NA
Pre-BD FEV1 pp, Mean (SD)	1.53 (0.46)	1.48 (0.39)	1.49 (0.41)	1.52 (0.48)	1.45 (0.39)	1.47 (0.42)	1.79 (0.61)
FEV1 Reversibility, Mean (SD)	18.34 (14.89)	23.47 (21.00)	21.79 (19.34)	18.61 (14.92)	24.52 (22.89)	22.59 (20.78)	26.41 (20.62)
ACQ5-1A, Mean (SD) [0-6]	2.15 (0.84)	2.18 (0.79)	2.17 (0.81)	2.17 (0.86)	2.18 (0.83)	2.18 (0.84)	2.77 (0.78)
ACQ7-1A, Mean (SD) [0-6]	2.12 (0.76)	2.15 (0.70)	2.14 (0.72)	2.15 (0.77)	2.16 (0.73)	2.16 (0.75)	2.87 (0.70)

FIG. 8

	Type 2 Population			Eos ≥ 300 Population			Quest (T2)
	PBO (N=114)	Dupi (N=236)	All (N=350)	PBO (N=84)	Dupi (N=175)	All (N=259)	T2 (1519)
With Ongoing Atopic Med Condition, n (%)	103 (90.4%)	226 (95.8%)	329 (94.0%)	79 (94.0%)	171 (97.7%)	250 (96.5%)	1208 (79.5)
Atopic Dermatitis, n (%)	41 (36.0%)	95 (40.3%)	136 (38.9%)	35 (41.7%)	80 (45.7%)	115 (44.4%)	171 (11.3)
Allergic Conjunctivitis, n (%)	22 (19.3%)	45 (19.1%)	67 (19.1%)	19 (22.6%)	40 (22.9%)	59 (22.8%)	217 (14.3)
Allergic Rhinitis, n (%)	89 (78.1%)	200 (84.7%)	289 (82.6%)	68 (81.0%)	154 (88.0%)	222 (85.7%)	1058 (69.7)
EoE, n (%)	0	3 (1.3%)	3 (0.9%)	0	2 (1.1%)	2 (0.8%)	3 (0.2)
Food Allergy, n (%)	18 (15.8%)	51 (21.6%)	69 (19.7%)	12 (14.3%)	39 (22.3%)	51 (19.7%)	133 (8.8)
Hives, n (%)	4 (3.5%)	19 (8.1%)	23 (6.6%)	3 (3.6%)	15 (8.6%)	18 (6.9%)	79 (5.2)
Baseline Blood eos (Giga/L), Mean (SD)	0.52 (0.36)	0.60 (0.39)	0.57 (0.38)	0.64 (0.35)	0.74 (0.36)	0.71 (0.36)	0.43 (0.38)
Eos ≥ 0.15 Giga/L	108 (94.7)	223 (94.5)	331 (94.6)	84 (100%)	175 (100%)	259 (100%)	1358 (89.4)
Eos > 0.15 Giga/L	6 (5.3%)	13 (5.5%)	19 (5.4%)	0	0	0	160 (10.5)
Baseline FeNO (ppb), Mean (SD)	28.38 (23.44)	31.83 (24.85)	30.71 (24.42)	31.33 (23.52)	3.53 (25.83)	33.50 (25.11)	40.2 (34.71)
FeNo ≥ 20 (25 in Adults), n (%)	62 (54.4)	141 (59.8)	203 (58.0)	52 (61.9)	114 (65.1)	166 (64.1)	943 (62.1)
FeNo < 20 (25 in Adults), n (%)	48 (42.1)	89 (37.7)	137 (39.1)	28 (33.3)	55 (31.4)	83 (32.0)	560 (36.7)
Serum Total IgE (IU/L), Median	397.00	530.00	483.00	554.00	599.50	586.00	195.00
TARC (PG/ML), Median	416.50	403.00	406.00	420.00	422.50	422.50	316

FIG. 9




FIG. 10




FIG. 10
(Continued)




FIG. 11




FIG. 11
(Continued)




FIG. 12

	Type 2		Eos > 0.3 Giga/L	
Subgroup	PBO (N=114)	Dupilumab (N=236)	PBO (N=84)	Dupilumab (N=175)
Patients with SCS Intake (%)	46 (40.4%)	57 (24.2%)	35 (41.7%)	39 (22.3%)
In Patients with SCS Intake:				
Mean (SD) of Individual Annualized Total SCS Duration (Days) ⁱ	11.01 (7.71)	8.63 (8.17)	11.48 (8.49)	8.08 (6.76)
Median of Individual Annualized Adjusted SCS Duration (Days)	9.89	5.02	9.82	5.00
Mean (SD) of Total SCS Courses	2.00 (1.15)	1.67 (1.12)	2.03 (1.25)	1.56 (1.02)
All Pooled Efficacy Patients:				
Mean (SD) of Individual Annualized Total SCS Duration (Days) ^a	4.44 (7.29)	2.08 (5.44)	4.78 (7.87)	1.80 (4.62)
Unadjusted annualized Total SCS Courses in all Pooled Efficacy Patients ⁱⁱ	0.816	0.414	0.859	0.361
i) The Total Dose/Number of SCS Days for Each Patient Divided by the Number of Patient-Years Followed in the Treatment Period for that Patient.; ii) The Total Number of SCS Courses During the Treatment Period Divided by the Number of Patient-Years Followed in the Treatment Period for that Patient				

FIG. 13




FIG. 14




FIG. 15




FIG. 15
(Continued)






FIG. 16






#Subjects
Placebo 114 110 113 113 110 112 112 112 110 111 106 109 110 110
Dupilumab 236 226 227 229 227 223 228 225 223 218 220 215 219 222

ACQ-7 @ wk 52	PBO	Dupilumab	OR/P Value
Responder ($\Delta > 0.5$)	85/114 (74.6%)	204/236 (86.4%)	2.57 (1.33, 4.98); P=0.005
ACQ7 ≤ 0.75	52/114 (45.6%)	164/236 (69.5%)	3.00 (1.79, 5.01); P<.0001

FIG. 18



#Subjects
Placebo 84 81 83 83 82 82 82 82 80 81 76 80 80 80
Dupilumab 175 166 168 169 167 164 168 165 163 160 161 157 160 163

ACQ-7 @ wk 52	PBO	Dupilumab	OR/P Value
Responder ($\Delta > 0.5$)	59/84 (70.2%)	152/175 (86.9%)	3.67 (1.70, 7.94); P=0.0009
ACQ7 ≤ 0.75	34/84 (40.5%)	118/175 (67.4%)	3.29 (1.78, 6.07); P=0.0001

FIG. 18 (Continued)

29/81




FIG. 19




FIG. 20




FIG. 21




FIG. 22

33/81




FIG. 23




FIG. 24




FIG. 25





FIG. 26






FIG. 27




FIG. 27 (Continued)





FIG. 28




42/81

FEV1pp Slope After Week 8

Rate of Change in Post-Bronchodilator % Predicted FEV1 from Baseline (Post-Bronchodilator % Predicted FEV1 Slope) After Week 8 - Type 2 Inflammatory Asthma Phenotype Population and Baseline Blood eosinophils >=0.3 Giga/L Population				
	Type 2 inflammatory Asthma Phenotype Population		Baseline Blood Eosinophils >=0.3 Giga/L Population	
	Placebo (N=114)	Dupilumab (N=236)	Placebo (N=84)	Dupilumab (N=175)
Post-Bronchodilator % Predicted FEV1 Slope During the 52-Week Treatment Period After Week 8 (%Year) ^a				
Number	113	230	83	170
Mean (SD)	0.194(14.623)	0.724(20.100)	1.042(15.039)	0.641(22.290)
Median	-1.053	-1.136	-0.362	-1.704
Q1 : Q3	-6.804 : 6.257	-7.302 : 7.733	-6.522 : 6.828	-8.172 : 8.700
Min : Max	-44.96 : 40.66	-103.96 : 148.17	-44.96 : 40.66	-103.96 : 148.17
Estimated Post-Bronchodilator % Predicted FEV1 Slope ^b	-0.45(1.76)	1.13(1.22)	0.09(2.26)	1.20(1.58)
LS Mean Diff vs. Matching Place (95% CI) ^b		1.57(-2.65, 5.79)		1.10(-4.33, 6.54)
P-Value vs. Matching Placebo ^b		0.4638		0.6894

BD, Bronchodilator; BL, Baseline; FEV₁, Forced Expiratory Volume in 1 Second; FEV1pp, Forced Expiratory Volume in 1 Second Percent Predicted.

FIG. 29






FIG. 30








FIG. 31









#Subjects													
Placebo	84	80	82	81	82	82	82	82	81	78	78	76	76
	78	82	82										
Dupilumab	175	165	167	168	165	164	164	160	158	158	154	158	158
	171	167	167	167	168	162	159						

FIG. 33
(Continued)







FIG. 34

[illegible]








#Subjects

Placebo	114	114	114	113	112	113	112	111	109	110	111	110	111	111
	114	114	114	113	110	113	110	111	109	111	111	110	110	110
Dupilumab	236	232	232	227	227	227	224	222	222	222	220	218	218	218
	234	232	230	228	228	225	223	222	222	222	219	218	219	219

FIG. 38




#Subjects

Placebo 84 84 84 83 82 83 82 81 80 80 81 81 80 81

Dupilumab 175 171 171 167 167 167 164 162 162 162 161 159 159 159

173 171 169 169 168 166 163 162 162 160 159 161 160


FIG. 39



#Subjects

Placebo	114	114	113	113	113	111	111	110	111	111	110	110	110
	114	114	113	113	112	113	110	111	110	111	110	110	111
Dupilumab	236	233	231	229	227	228	226	224	221	222	220	217	219
	234	232	230	228	228	224	223	224	224	220	219	219	219

FIG. 40



#Subjects

Placebo 84 84 84 83 83 83 82 81 81 80 81 81 80 81

Dupilumab 175 172 170 169 167 168 166 164 162 162 161 158 160 161
173 171 169 169 168 165 163 164 164 161 160 161 160

FIG. 41





FIG. 42



#Subjects

Placebo	78	73	71	74	75
Dupilumab	152	144	142	136	137

FIG. 42
(Continued)

60/81




FIG. 43




FIG. 44






FIG. 45









FIG. 48



#Subjects


114 114 114 113 112 113 112 111 109 110 111 111 111 111
114 114 114 113 111 113 110 111 109 111 111 111 111

Placebo

236 232 232 229 229 228 226 225 224 224 223 221 220 221
234 232 230 229 227 226 225 224 223 222 220 221

Dupilumab

FIG. 49



#Subjects

Placebo	84	84	84	83	82	81	80	80	81	81	81	81
Dupilumab	175	171	171	168	169	168	166	165	164	163	161	162
	173	171	169	170	169	167	166	165	164	163	162	161

FIG. 49
(Continued)




114 114 114 113 113 112 111 111 110 111 111 110 110
114 114 113 112 113 110 111 110 111 111 110 111

Placebo

Dupilumab


50
G[®]
E



#Subjects

Placebo	84	84	84	83	83	82	81	81	80	81	81	80	80	
Dupilumab	175	172	170	170	169	169	168	167	166	164	163	160	161	162
	173	171	169	170	169	166	166	166	166	166	164	163	161	162


FIG. 50
(Continued)



#Subjects

Placebo	114	114	114	113	112	111	109	110	111	111	111	111
	114	114	114	113	111	113	110	111	109	111	111	111
Dupilumab	236	232	232	229	228	226	225	224	224	223	221	220
	234	232	230	229	227	226	225	224	223	222	220	221


FIG. 51



#Subjects

Placebo	84	84	84	83	82	83	82	81	80	80	81	81	81	81
	84	84	84	83	82	83	81	81	79	81	81	81	81	81
Dupilumab	175	171	171	168	169	168	166	166	165	164	164	163	161	162
	173	171	169	170	169	167	166	166	165	164	163	162	161	162


FIG. 51
(Continued)



#Subjects

Placebo	114	114	114	113	112	112	112	111	109	109	111	110	108	109
	114	114	114	113	111	112	109	110	108	110	110	110	110	109
Dupilumab	236	232	230	228	228	226	225	222	221	222	222	218	217	215
	233	232	229	229	225	225	223	223	223	219	219	218	217	215

FIG. 52




#Subjects

Placebo 84 84 84 83 82 82 81 80 79 81 80 78 79

Dupilumab 175 171 169 167 168 166 165 162 161 162 162 158 156
172 171 168 169 165 165 163 164 163 159 159 158 158


FIG. 52
(Continued)



#Subjects
Placebo 132
Dupilumab 267

126
245

FIG. 53



#Subjects	132	133	130	127
Placebo				
Dupilumab	268	260	254	244

FIG. 54





FIG. 55A



#Subjects	132	131	129	126
Placebo	132	131	129	126
Dupilumab	268	257	252	242

FIG. 54
(Continued)




FIG. 55B




FIG. 56A




FIG. 56B

Overall Number of Participants		Placebo	Dupilumab	Total
Age, Continuous Measure: Mean (Standard Deviation) Unit of Measure: Years	Number Analyzed	135	273	408
		135 Participants	273 Participants	408 Participants
		8.9 (1.6)	8.9 (1.7)	8.9 (1.6)
Sex: Female, Male Measure: Count of Participants Unit of Measure: Participants	Number Analyzed	135 Participants	273 Participants	408 Participants
	Female	48 35.56%	98 35.9%	146 35.78%
	Male	87 64.44%	175 64.1%	262 64.22%
Race/Ethnicity, Customized Measure: Count of Participants Unit of Measure: Participants	Number Analyzed	135 Participants	273 Participants	408 Participants
	Race			
	Caucasian/White	118	242	360
	Black/of African Descent	9	11	20
	Asian/Oriental	0	2	2
	American Indian or Alaska Native	0	1	1
Other		8	17	25

FIG. 57